CurveBeam AI Ltd.ASX: CVB

Quarterly Activities/Appendix 4C Cash Flow Report

· Issued by CurveBeam AI Ltd. via ASX

Filed with ASX · · 10 pages · English

Summary by 6ix AI

The report highlights the receipt of purchase orders for five HiRise™ devices and FDA clearance for its Bone Mineral Density technology. Additionally, Curvebeam Ai is advancing its strategy in China, having received regulatory clearance that is expected to trigger significant milestone payments.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX ANNOUNCEMENT ASX: CVB st 21 October 2026 Appendix 4C & quarterly activity report – period ended 30 September 2026 Summary of key activities • Purchase orders (POs) secured during Q1 FY27 totalled five (5) devices, all HiRise™ systems, marking the strongest Q1 sales result to date. •...

CurveBeam AI Ltd. on 6ix

In the deck

Story so far

Earlier from CurveBeam AI

Later from CurveBeam AI

All CurveBeam AI news releases